Form 4: Clene Director Boosts Stake with New Share and Warrant Purchase

Clene Inc. Director Alison Mosca, through an affiliated LLC, acquired additional common stock and warrants, signaling increased insider confidence.

Summary

• Alison Mosca, a Director of Clene Inc., reported changes in her beneficial ownership.
• Kensington Clene 2021, LLC, managed by Ms. Mosca, acquired 16,667 shares of Clene Inc. common stock, 20,000 Series A Warrants, and 46,667 Series B Warrants on January 13, 2026.
• This acquisition was part of a Securities Purchase Agreement where each unit, consisting of one common share, one Series A Warrant, and one Series B Warrant, was priced at $6.50.
• The LLC also distributed 57,219 shares of common stock, 57,219 Tranche B Warrants, and 57,219 Tranche A Warrants to a limited partner on January 9, 2026, for no consideration.
• Ms. Mosca's indirect beneficial ownership includes shares held by Kensington Clene 2021, LLC (280,500 shares), Kensington Investments, L.P. (150,333 shares), and the Robert C. Gay 1998 Family Trust (72,997 shares), in addition to her direct ownership of 1,973 shares.
• Ms. Mosca disclaims beneficial ownership for shares held by these entities in which she does not have a pecuniary or profits interest.

Sentiment

Score: 7

Explanation: The acquisition of common stock and new warrants by a director, through an affiliated entity, indicates a strong vote of confidence in the company's future prospects, despite the complexity of warrant terms and the distribution of some existing holdings.

Positives

• A Director, through an affiliated entity, increased their stake in Clene Inc. by acquiring 16,667 common shares and 66,667 new warrants, signaling confidence in the company's future.
• The acquisition was made at a unit price of $6.50, which includes common stock and two types of warrants, indicating a strategic investment.

Negatives

• The complexity of the warrant terms, particularly the variable exercise prices tied to FDA milestones and stock performance, introduces uncertainty regarding potential future dilution and the ultimate cost of exercising these derivatives.
• The distribution of 57,219 common shares and 114,438 existing warrants from Kensington Clene 2021, LLC to a limited partner, while for no consideration, represents a reduction in the LLC's direct holdings.

Risks

• The exercise prices of the Series A and Series B Warrants are contingent on future FDA actions (NDA acceptance/approval for CNM-Au8) and the company's stock price (VWAP thresholds of $10, $20, $25), introducing significant uncertainty regarding their future value and potential dilution.
• The Tranche A and Tranche B Warrants also have expiration dates tied to FDA milestones, specifically FDA acceptance or approval of a New Drug Application, which are inherently uncertain events.

Future Outlook

The future value and exercise conditions of the acquired Series A and Series B Warrants are directly tied to the U.S. Food and Drug Administration's (FDA) progress on Clene Inc.'s New Drug Application (NDA) for CNM-Au8, specifically the public announcement of the FDA's action date, acceptance, and ultimate approval for CNM-Au8 in ALS. The exercise prices for these warrants will increase if certain FDA milestones are met or if the company's stock price reaches specified volume-weighted average price (VWAP) thresholds.

Management Comments

• Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.
• Ms. Mosca disclaims all shares owned by Kensington Investments, L.P., for which she does not have a pecuniary or profits interest.
• Ms. Mosca has no pecuniary or profits interest in the shares held by the Robert C. Gay 1998 Family Trust.

Industry Context

This insider transaction occurs within the biopharmaceutical industry, where company valuations and stock performance are heavily influenced by clinical trial results, regulatory milestones, particularly FDA approvals, and the commercialization potential of drug candidates like CNM-Au8. The warrant terms explicitly linking exercise prices and expiration dates to FDA actions underscore the critical role of regulatory progress in this sector.

Comparison to Industry Standards

• Insider purchases, especially by directors, are generally viewed as a positive signal, suggesting management's belief in the company's future prospects, aligning with common investor sentiment.
• The structure of the investment, combining common stock with warrants, is a common financing mechanism in the biotech sector, allowing investors to participate in upside potential while providing capital to the company.
• The contingent exercise prices of the warrants, tied to FDA milestones and stock performance, are typical for early-stage biopharma investments, reflecting the high-risk, high-reward nature of drug development. This type of structured financing is frequently observed in emerging biopharmaceutical companies seeking to fund research and development, where future regulatory success is a primary value driver.

Related Party Transactions

• Alison Mosca, a Director, is the sole manager of and owns a minority interest in Kensington Clene 2021, LLC, which engaged in the reported transactions.
• Ms. Mosca is the chief executive officer of Kensington Investments, L.P., which beneficially owns Clene Inc. shares.
• Ms. Mosca is the trustee of the Robert C. Gay 1998 Family Trust, which beneficially owns Clene Inc. shares.

Stakeholder Impact

• Shareholders: The insider purchase could be seen as a positive signal, potentially boosting investor confidence. However, the future exercise of warrants could lead to dilution.
• Company (Clene Inc.): The Securities Purchase Agreement represents a capital raise, providing funds for operations and development.
• Warrant Holders (Kensington Clene 2021, LLC): The value of their warrants is directly tied to the company's stock performance and FDA regulatory success, offering significant upside potential if milestones are met.

Next Steps

• Monitoring of FDA's progress on Clene Inc.'s New Drug Application (NDA) for CNM-Au8, including the public announcement of the FDA's action date, acceptance, and ultimate approval.
• Observation of Clene Inc.'s common stock volume-weighted average price (VWAP) in relation to the $10, $20, and $25 thresholds, which could trigger increases in warrant exercise prices.

Key Dates

Recommendation

The significant investment by a director, through an affiliated entity, in both common stock and warrants, signals strong insider confidence in Clene Inc.'s future. While the warrant terms are complex and tied to FDA milestones, the willingness of an insider to increase their stake at this juncture suggests a belief in the company's potential for positive regulatory outcomes and stock appreciation. This insider buying activity, especially when coupled with a capital raise, often precedes favorable developments and warrants a 'buy' recommendation for investors seeking exposure to the biopharma sector with a positive insider sentiment.

Keywords

Clene Inc., CLNN, Alison Mosca, Director, Insider Trading, Form 4, Beneficial Ownership, Common Stock, Warrants, Securities Purchase Agreement, FDA, CNM-Au8, Biopharma, Investment